The American Academy of Neurology (AAN) and American Headache Society (AHS) have issued an updated practice guideline on ...

Welcome to NeurologyLive® 's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive 's widespread coverage in ...

FDA approval of apitegromab introduces a muscle-targeting approach to SMA treatment, with phase 3 data demonstrating ...

Sports neurologist Rory Siegel, DO, discusses the emerging evidence linking football participation with ALS, the potential role of repetitive head impacts, and key questions that remain about ...

The FDA granted priority review to satralizumab for MOGAD, positioning it to become the first approved treatment for the rare ...

FDA approval of apitegromab introduces a muscle-targeting approach to SMA treatment, with phase 3 data demonstrating motor-function benefit when added to existing SMN2-directed therapies. The FDA ...

The phase 3 LUNA study showed that atogepant, an oral calcitonin gene-related peptide receptor antagonist, significantly reduced perimenstrual migraine days among patients with menstrual migraine ...

A new study suggests excessive daytime sleepiness in obstructive sleep apnea may be associated with cognitive impairment and ...

The AAN and AHS have replaced their 2012 migraine prevention guideline with new, evidence-graded recommendations, giving neurologists clearer direction on when to start preventive therapy, how to ...

The clinical neuropsychologist and assistant professor of medicine at the Icahn School of Medicine at Mount Sinai discussed the mechanisms behind brain fog from Long COVID and its potential links to ...

Findings newly published in the Journal of Neurology, Neurosurgery & Psychiatry indicated that the long-standing clinical ...

A 72% prevalence of excessive daytime sleepiness was identified using PDSS ≥15 among 1,616 adolescents aged 14–19 years in 20 ...